We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Intuitive Surgical for Now
Read MoreHide Full Article
Intuitive Surgical, Inc. (ISRG - Free Report) is well poised for growth on improving adoption of da Vinci Surgical System, strong international presence and solid recurring revenue base. However, contraction in margins remains a concern.
The company currently carries a Zacks Rank #3 (Hold).
Price Performance
Shares of Intuitive Surgical have gained 10.3% compared with the industry’s growth of 10.5% on a year-to-date basis. Meanwhile, the S&P 500 Index has rallied 17.1% in the same timeframe.
What’s Deterring the Stock?
Intuitive Surgical has been witnessing contraction in margins for time quite some time now. Management expects margins to fluctuate based on a mix of new products and systems. Further, the company is incurring additional costs for expansion in markets outside the United States, which in turn is adding to woes.
What’s Favoring the Stock?
Intuitive Surgical’s robot-based da Vinci surgical system enables minimally-invasive surgery, which reduces risks associated with open surgery. The company continues to gain from this system, which in turn boosts overall performance.
In the second quarter of 2019, da Vinci procedure improved 17% globally from the second quarter of last year. This was driven by healthy growth in U.S. General Surgery. In the last reported quarter, Intuitive Surgical placed 273 da Vinci surgical systems, with the installed base growing 13% year over year to approximately 5,270. In fact, it now forecasts 2019 procedure growth to be 16-17% compared with the previously anticipated rise of 15-17%.
Intuitive Surgical is gradually gaining prominence in markets outside the United States. In the second quarter of 2019, international revenues rose 19% year over year, owing to solid show by the Instruments & Accessories segment.
Notably, the segment grew on solid procedure growth and customer buying patterns. Intuitive Surgical placed 80 systems in the second quarter of 2019 compared with 82 units in the second quarter of 2018. Of these, 30 were in Europe, 24 in Japan and eight in China.
Intuitive Surgical’s business model ensures that it continues to generate revenues from initial capital sales of da Vinci Surgical Systems, and subsequent sales of instruments, accessories and services. In the second quarter, total recurring revenues were $780 million, up 21% year over year and accounting for a whopping 71% of total revenues.
Recurring revenues, as a proportion of total revenues, continue to grow at a much higher rate as compared with system sales. This ensures a regular stream of income, even in testing times. Moreover, Intuitive Surgical operates in a niche MedTech market, with no direct competition, which is a major positive.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $4.33 billion, indicating an improvement of 16.3% from the year-ago quarter. The same for earnings stands at $10.12 per share, suggesting growth of 6.6% from the year-ago reported figure.
Nissan Chemical has a long-term earnings growth rate of 10%.
Straumann Holding has a long-term earnings growth rate of 18%.
McKesson has a long-term earnings growth rate of 6.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Here's Why You Should Retain Intuitive Surgical for Now
Intuitive Surgical, Inc. (ISRG - Free Report) is well poised for growth on improving adoption of da Vinci Surgical System, strong international presence and solid recurring revenue base. However, contraction in margins remains a concern.
The company currently carries a Zacks Rank #3 (Hold).
Price Performance
Shares of Intuitive Surgical have gained 10.3% compared with the industry’s growth of 10.5% on a year-to-date basis. Meanwhile, the S&P 500 Index has rallied 17.1% in the same timeframe.
What’s Deterring the Stock?
Intuitive Surgical has been witnessing contraction in margins for time quite some time now.
Management expects margins to fluctuate based on a mix of new products and systems. Further, the company is incurring additional costs for expansion in markets outside the United States, which in turn is adding to woes.
What’s Favoring the Stock?
Intuitive Surgical’s robot-based da Vinci surgical system enables minimally-invasive surgery, which reduces risks associated with open surgery. The company continues to gain from this system, which in turn boosts overall performance.
In the second quarter of 2019, da Vinci procedure improved 17% globally from the second quarter of last year. This was driven by healthy growth in U.S. General Surgery. In the last reported quarter, Intuitive Surgical placed 273 da Vinci surgical systems, with the installed base growing 13% year over year to approximately 5,270. In fact, it now forecasts 2019 procedure growth to be 16-17% compared with the previously anticipated rise of 15-17%.
Intuitive Surgical is gradually gaining prominence in markets outside the United States. In the second quarter of 2019, international revenues rose 19% year over year, owing to solid show by the Instruments & Accessories segment.
Notably, the segment grew on solid procedure growth and customer buying patterns. Intuitive Surgical placed 80 systems in the second quarter of 2019 compared with 82 units in the second quarter of 2018. Of these, 30 were in Europe, 24 in Japan and eight in China.
Intuitive Surgical’s business model ensures that it continues to generate revenues from initial capital sales of da Vinci Surgical Systems, and subsequent sales of instruments, accessories and services. In the second quarter, total recurring revenues were $780 million, up 21% year over year and accounting for a whopping 71% of total revenues.
Recurring revenues, as a proportion of total revenues, continue to grow at a much higher rate as compared with system sales. This ensures a regular stream of income, even in testing times. Moreover, Intuitive Surgical operates in a niche MedTech market, with no direct competition, which is a major positive.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $4.33 billion, indicating an improvement of 16.3% from the year-ago quarter. The same for earnings stands at $10.12 per share, suggesting growth of 6.6% from the year-ago reported figure.
Key Picks
Some better-ranked stocks from the broader medical space are Nissan Chemical Corporation (NNCHY - Free Report) , Straumann Holding AG and McKesson Corporation (MCK - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Nissan Chemical has a long-term earnings growth rate of 10%.
Straumann Holding has a long-term earnings growth rate of 18%.
McKesson has a long-term earnings growth rate of 6.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>